Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of “Buy” from Analysts
Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) has earned an average recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among […]
Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) has earned an average recommendation of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among […]
